Complete financial analysis of Electromed, Inc. (ELMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Electromed, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- The Australian Wealth Advisors (WAG.AX) Income Statement Analysis – Financial Results
- Public Joint Stock Company “Rollman Group” (RLMN.ME) Income Statement Analysis – Financial Results
- Impel Pharmaceuticals Inc. (IMPL) Income Statement Analysis – Financial Results
- Yes Optoelectronics (Group) Co., Ltd. (002952.SZ) Income Statement Analysis – Financial Results
- Genfit S.A. (GNFTF) Income Statement Analysis – Financial Results
Electromed, Inc. (ELMD)
About Electromed, Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.72M | 48.07M | 41.66M | 35.76M | 32.47M | 31.30M | 28.70M | 25.86M | 22.99M | 19.41M | 15.49M | 15.10M | 19.52M | 19.00M | 14.30M | 13.00M | 8.75M |
| Cost of Revenue | 12.99M | 11.55M | 10.22M | 8.45M | 7.27M | 7.45M | 5.84M | 5.29M | 5.12M | 5.81M | 4.85M | 4.66M | 5.38M | 5.23M | 3.71M | 3.34M | 2.15M |
| Gross Profit | 41.73M | 36.52M | 31.44M | 27.31M | 25.20M | 23.85M | 22.86M | 20.57M | 17.88M | 13.60M | 10.63M | 10.45M | 14.15M | 13.78M | 10.60M | 9.66M | 6.61M |
| Gross Profit Ratio | 76.26% | 75.98% | 75.47% | 76.36% | 77.61% | 76.19% | 79.64% | 79.53% | 77.75% | 70.07% | 68.66% | 69.18% | 72.45% | 72.50% | 74.08% | 74.30% | 75.47% |
| Research & Development | 656.00K | 916.00K | 1.36M | 1.72M | 1.05M | 583.31K | 251.44K | 596.88K | 380.39K | 315.65K | 466.06K | 603.38K | 920.77K | 1.03M | 600.99K | 357.87K | 271.24K |
| General & Administrative | 33.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.60M | 16.40M | 14.39M | 11.97M | 10.91M | 11.67M | 12.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 499.00K | 589.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.49M | 31.60M | 27.11M | 22.44M | 19.94M | 20.45M | 19.60M | 16.40M | 14.39M | 11.97M | 10.91M | 11.67M | 12.62M | 10.87M | 8.20M | 6.85M | 6.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -12.00K | -913.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.87M | 8.20M | 6.85M | 6.00M |
| Operating Expenses | 35.15M | 32.51M | 28.47M | 24.17M | 20.08M | 21.03M | 19.85M | 17.00M | 14.77M | 12.29M | 11.37M | 12.28M | 13.54M | 11.91M | 8.80M | 7.20M | 6.27M |
| Cost & Expenses | 48.14M | 44.06M | 38.69M | 32.62M | 27.35M | 28.48M | 25.69M | 22.29M | 19.88M | 18.10M | 16.23M | 16.93M | 18.92M | 17.13M | 12.51M | 10.54M | 8.42M |
| Interest Income | 455.00K | 78.00K | 25.00K | 39.00K | 120.75K | 90.71K | 0.00 | 17.04K | 0.00 | 284.00 | 12.39K | 16.72K | 8.40K | 10.92K | 6.42K | 8.75K | 24.82K |
| Interest Expense | 0.00 | 0.00 | 25.00K | 0.00 | 0.00 | 0.00 | 19.87M | 66.91K | 66.81K | 85.99K | 91.40K | 133.56K | 177.13K | 191.33K | 269.85K | 279.19K | 501.69K |
| Depreciation & Amortization | 841.00K | 613.00K | 628.00K | 610.00K | 738.23K | 925.23K | 790.03K | 755.13K | 738.70K | 736.22K | 695.55K | 589.86K | 532.63K | 449.47K | 351.75K | 318.95K | 268.40K |
| EBITDA | 7.42M | 4.62M | 3.60M | 3.75M | 5.86M | 3.74M | 3.80M | 4.32M | 3.85M | 2.05M | -32.65K | -1.24M | 1.15M | 2.33M | 2.15M | 2.77M | 627.43K |
| EBITDA Ratio | 13.56% | 9.61% | 8.64% | 10.49% | 18.04% | 11.96% | 13.24% | 16.72% | 16.74% | 10.54% | -0.21% | -8.08% | 5.88% | 12.21% | 15.06% | 21.41% | 7.17% |
| Operating Income | 6.58M | 4.01M | 2.97M | 3.14M | 5.12M | 2.82M | 3.01M | 3.57M | 3.11M | 1.31M | -740.59K | -1.83M | 606.34K | 1.87M | 1.80M | 2.46M | 334.22K |
| Operating Income Ratio | 12.03% | 8.34% | 7.13% | 8.78% | 15.76% | 9.00% | 10.48% | 13.80% | 13.52% | 6.75% | -4.78% | -12.10% | 3.11% | 9.84% | 12.56% | 18.89% | 3.82% |
| Total Other Income/Expenses | 455.00K | 78.00K | 25.00K | 27.00K | 120.75K | 101.82K | -276.35K | -49.87K | -66.81K | -85.71K | -79.00K | -116.88K | -168.73K | -191.33K | -263.43K | -270.45K | -476.87K |
| Income Before Tax | 7.04M | 4.09M | 3.00M | 3.17M | 5.24M | 2.91M | 3.03M | 3.52M | 3.04M | 1.22M | -819.59K | -1.94M | 437.61K | 1.68M | 1.53M | 2.19M | -142.65K |
| Income Before Tax Ratio | 12.86% | 8.50% | 7.19% | 8.86% | 16.14% | 9.29% | 10.55% | 13.61% | 13.23% | 6.31% | -5.29% | -12.87% | 2.24% | 8.83% | 10.71% | 16.81% | -1.63% |
| Income Tax Expense | 1.89M | 920.00K | 692.00K | 805.00K | 1.08M | 940.00K | 1.13M | 1.29M | 830.00K | 132.00K | 469.00K | -615.00K | 251.00K | 623.00K | 599.00K | 830.00K | -427.00K |
| Net Income | 5.15M | 3.17M | 2.31M | 2.36M | 4.16M | 1.97M | 1.90M | 2.23M | 2.21M | 1.09M | -1.29M | -1.33M | 186.61K | 1.06M | 916.34K | 1.33M | 267.85K |
| Net Income Ratio | 9.41% | 6.59% | 5.53% | 6.61% | 12.81% | 6.29% | 6.63% | 8.62% | 9.62% | 5.63% | -8.32% | -8.80% | 0.96% | 5.55% | 6.41% | 10.25% | 3.06% |
| EPS | 0.60 | 0.37 | 0.27 | 0.28 | 0.50 | 0.24 | 0.23 | 0.27 | 0.27 | 0.13 | -0.16 | -0.16 | 0.02 | 0.14 | 0.15 | 0.22 | 0.05 |
| EPS Diluted | 0.58 | 0.36 | 0.26 | 0.27 | 0.47 | 0.23 | 0.22 | 0.26 | 0.27 | 0.13 | -0.16 | -0.16 | 0.02 | 0.13 | 0.15 | 0.22 | 0.04 |
| Weighted Avg Shares Out | 8.56M | 8.46M | 8.47M | 8.57M | 8.40M | 8.31M | 8.21M | 8.17M | 8.14M | 8.12M | 8.05M | 8.11M | 8.11M | 7.82M | 6.08M | 5.99M | 5.44M |
| Weighted Avg Shares Out (Dil) | 8.86M | 8.70M | 8.77M | 8.91M | 8.83M | 8.63M | 8.62M | 8.46M | 8.25M | 8.15M | 8.11M | 8.11M | 8.11M | 7.84M | 6.11M | 6.02M | 6.45M |
Electromed, Inc. Schedules its First Quarter Fiscal 2024 Financial Results Conference Call for November 7, 2023 at 5:00 p.m. ET
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Schedules its First Quarter Fiscal 2024 Financial Results Conference Call for November 7, 2023 at 5:00 p.m. ET.
Electromed, Inc. (ELMD) Q4 2023 Earnings Call Transcript
Electromed, Inc. (NYSE:ELMD ) Q4 2023 Earnings Call Transcript August 22, 2023 5:00 PM ET Company Participants Mike Cavanaugh - IR Jim Cunniff - President and CEO Brad Nagel - CFO Conference Call Participants Brooks O'Neil - Lake Street Operator...
Electromed, Inc. Announces Fiscal 2023 Fourth Quarter and Full Year Financial Results
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Fiscal 2023 Fourth Quarter and Full Year Financial Results.
Electromed Announces Grant of Inducement Equity Awards
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed Announces Grant of Inducement Equity Awards.
Electromed: May Reversal Vindicating Long-Term Buy Thesis
Electromed continues to rally off previous lows and crossed above the 50DMA last week. SmartVest numbers are ratcheting higher, CMS waiver decision well priced into the equity level.
Electromed, Inc. (ELMD) Q3 2023 Earnings Call Transcript
Electromed, Inc. (NYSE:ELMD ) Q3 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Mike Cavanaugh - Investor Relations Kathleen Skarvan - President and Chief Executive Officer Brad Nagel - Chief Financial Officer Conference Call Participants Brooks...
Electromed, Inc. Schedules its Third Quarter Fiscal 2023 Financial Results Conference Call for May 9, 2023 at 5:00 p.m. ET
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Schedules its Third Quarter Fiscal 2023 Financial Results Conference Call for May 9, 2023 at 5:00 p.m. ET.
Electromed: Reiterating Buy With Sales Rep Conversions Driving Top-Line Growth
Solid Q2 result with upsides versus consensus at the top and bottom lines. Sales force increase converting to further sales growth with >$950,000 in revenue/rep this quarter.
Electromed, Inc. (ELMD) Q2 2023 Earnings Call Transcript
Electromed, Inc. (NYSE:ELMD ) Q2 2023 Earnings Conference Call February 14, 2023 5:00 PM ET Company Participants Mike Cavanaugh – Investor Relations Kathleen Skarvan – President and Chief Executive Officer Brad Nagel – Chief Financial Officer Conference Call Participants Brooks...
Electromed, Inc. Schedules its Second Quarter Fiscal 2023 Financial Results Conference Call for February 14, 2023 at 5:00 p.m. ET
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2023 second quarter ended December 31, 2022,...
Source: https://incomestatements.info
Category: Stock Reports